Biosimilars And The European Experience: Implications For The United States

Megerlin, Francis; Lopert, Ruth; Taymor, Ken; Trouvin, Jean‐Hugues

doi:10.1377/hlthaff.2009.0196

Cited by 37 publications

(38 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This migration is happening quite effectively for nonspecialty drugs subject to competition from generic copies, but has not arrived in the US for most infused and oral biopharmaceuticals. This competition, and the resulting impact on unit prices, will only emerge when a sufficient number of therapeutically similar branded and biosimilar drugs become available for the major forms of cancer [11].…”

Section: Resultsmentioning

confidence: 99%

Value and payment for oncology in the United States

Robinson¹

2013

Annales Pharmaceutiques Françaises

View full text Add to dashboard Cite

Summary Rather than focus on reducing prices for innovative biopharmaceuticals, insurers in the United States are changing methods of payment for oncologists in order to moderate the growth in cancer drug expenditures. The desire is for a better pattern of utilization and expenditures without adversely affecting incentives for research and development. After an overview of the contemporary discussions of price and value, this paper describes three initiatives to influence the selection and management of oncology drugs. This includes initiatives to reduce the profit margins earned by oncologists as part of the purchasing of office-infused biopharmaceuticals; ''episode-of-care'' payments that bundle into a single fee the reimbursement for care management and specialty drugs; and payment methods that case rates for physician care management activities with cost-based reimbursement for the oncology drugs. © 2013 Elsevier Masson SAS. All rights reserved. MOTS CLÉSMédicaments ; États-Unis ; Oncologie ; Prix ; Résumé Plutôt que de chercher à réduire le prix des médicaments innovants très onéreux, les assureurs américains développent actuellement de nouvelles méthodes de paiement des médecins qui, en oncologie par exemple, visent à une meilleure utilisation clinique et à la maîtrise des coûts d'usage des produits. Après un aperçu du débat actuel sur le prix et la valeur aux États-Unis dans ce domaine, cet article décrit trois initiatives : la limitation des marges commerciales jusqu'alors réalisées par les médecins qui prescrivent et administrent ces Performance ; Paiement ; Épisode de soins ; Management des soins médicaments, achetés aux producteurs puis refacturés aux assureurs ; l'approche en « épisodes de soins », qui consiste en un paiement globalisé des consultations médicales, du management des soins et des traitements médicamenteux ; et enfin une troisième approche mixte, qui consiste en le paiement différencié des honoraires pour les consultations, du management par cas des soins, avec facturation séparée des médicaments sur la base de leur coût.

show abstract

Section: Resultsmentioning

confidence: 99%

Value and payment for oncology in the United States

Robinson¹

2013

Annales Pharmaceutiques Françaises

View full text Add to dashboard Cite

show abstract

“…As the leading region for the development of biosimilars, the experience of European uptake of biosimilars is being explored regularly for indications of how biosimilars will ultimately find their place in healthcare provision (Blackstone and Fuhr 2012;Grabowski, Guha, and Salgado 2014;Megerlin et al 2013). However, one fundamental question is how to assess uptake of a biosimilar: Is that as a share of its reference medicine, as a share of medicines of a similar 'vintage' of technology for a given indication or as a share of all medicines used for that indication?…”

Section: Mapping the Second Translational Gapmentioning

confidence: 99%

Translating European regulatory approval into healthcare uptake for biosimilars: the second translational gap

Acha

Mestre-Ferrandiz

2017

Technology Analysis & Strategic Management

View full text Add to dashboard Cite

“…Biosimilars typically cost 25 percent less than comparable branded products in Europe and may enter the US market through the Food and Drug Administration's new regulatory approval pathway. 11 New firms are entering the global market for pharmaceuticals. Manufacturers in India, China, South Korea, and Israel are already proficient in manufacturing small-molecule generic drugs and are expanding their product development expertise to biosimilars.…”

Section: Design To Valuementioning

confidence: 99%

Biomedical Innovation In The Era Of Health Care Spending Constraints

Robinson

2015

Health Affairs

View full text Add to dashboard Cite

Insurers, hospitals, physicians, and consumers are increasingly weighing price against performance in their decisions to purchase and use new drugs, devices, and other medical technologies. This approach will tend to affect biomedical innovation adversely by reducing the revenues available for research and development. However, a more constrained funding environment may also have positive impacts. The passing era of largely cost-unconscious demand fostered the development of incremental innovations priced at premium levels. The new constrained-funding era will require medical technology firms to design their products with the features most valued by payers and patients, price them at levels justified by clinical performance, and manage distribution through organizations rather than to individual physicians. The emerging era has the potential to increase the social value of innovation by focusing industry on design, pricing, and distribution principles that are more closely aligned with the preferences-and pocketbooks-of its customers.

show abstract

Biosimilars And The European Experience: Implications For The United States

Cited by 37 publications

References 14 publications

Value and payment for oncology in the United States

Value and payment for oncology in the United States

Translating European regulatory approval into healthcare uptake for biosimilars: the second translational gap

Biomedical Innovation In The Era Of Health Care Spending Constraints

Contact Info

Product

Resources

About